Location · Wake Forest, NC
Clinical trials in Wake Forest, NC
12 recruiting studies have a site in Wake Forest, and 0 of them accept healthy volunteers.
12 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Merck Sharp & Dohme LLC
- Location
- Wake Forest, NC + 27 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
EyeBiotech Ltd.
- Location
- Wake Forest, NC + 54 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Sanofi
- Location
- Wake Forest, NC + 30 other US sites
- Eligibility basics
- Ages 60+
- RecruitingPhase 2
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
Boehringer Ingelheim
- Location
- Wake Forest, NC + 21 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
Boehringer Ingelheim
- Location
- Wake Forest, NC + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Amgen
- Location
- Wake Forest, NC + 54 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2/Phase 3
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Janssen Research & Development, LLC
- Location
- Wake Forest, NC + 44 other US sites
- Eligibility basics
- Ages 60+
- RecruitingPhase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Adverum Biotechnologies, Inc.
- Location
- Wake Forest, NC + 78 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
ONL Therapeutics
- Location
- Wake Forest, NC + 55 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2/Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
EyeBiotech Ltd.
- Location
- Wake Forest, NC + 51 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
Kodiak Sciences Inc
- Location
- Wake Forest, NC + 47 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
Kodiak Sciences Inc
- Location
- Wake Forest, NC + 47 other US sites
- Eligibility basics
- Ages 18+